News & Updates

Seladelpar safe, effective for primary biliary cholangitis
Seladelpar safe, effective for primary biliary cholangitis
10 Apr 2022

In patients with primary biliary cholangitis, the use of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, safely improves biochemical markers of cholestasis and inflammation, reports a new study.

Seladelpar safe, effective for primary biliary cholangitis
10 Apr 2022
Hepatitis B virus treatment rates still low among eligible patients
Hepatitis B virus treatment rates still low among eligible patients
10 Apr 2022